{"id":"88e03d154fd3","type":"article","url":"https://hartvaat.nl/2026/11/01/combinatietherapie-verbetert-overleving-bij-hiv-geassocieerde-pulmonale-hyperten/","title":"Combinatietherapie verbetert overleving bij hiv-geassocieerde pulmonale hypertensie — meta-analyse","title_en":"HIV-associated pulmonary arterial hypertension: improving survival despite persistent treatment gaps - a systematic review and meta-analysis.","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"AIDS (London, England)","doi":"10.1097/QAD.0000000000004595","source_url":"https://doi.org/10.1097/QAD.0000000000004595","authors":["Marcos Vinicius Fernandes Garcia","Tim Lahm"],"significance":5,"published":"2026-10-10","source_date":"2026-11-01","image":"https://hartvaat.nl/global/img/6e2cc0469790.webp","kennis":["https://hartvaat.nl/kennis/hypertensie/hypertensie-en-zwangerschap/","https://hartvaat.nl/kennis/hypertensie/esc-richtlijn-hypertensie-2024/"],"congress":"","summary_en":"A systematic review and meta-analysis of 12 cohorts (n=537) reveals that HIV-associated pulmonary arterial hypertension (HIV-PAH) presents with severe hemodynamic impairment and advanced functional limitation, with only 64% receiving PAH-targeted therapy at diagnosis. Despite this treatment gap, survival has progressively improved over the past three decades alongside increased therapy use. These findings underscore the need for earlier initiation of contemporary combination regimens in people living with HIV and PAH.","created":"2026-10-04T00:57:52Z","updated":"2026-10-04T00:57:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een systematische review en meta-analyse van 12 cohorts (n=537) toont aan dat hiv-geassocieerde pulmonale arteriële hypertensie (HIV-PAH) gepaard gaat met ernstige hemodynamische afwijkingen en beperkte functionele status. Alleen 64% van de patiënten ontving op het moment van diagnose al PAH-specifieke therapie, maar de overleving verbeterde de afgelopen drie decennia aanzienlijk in lijn met de toegenomen behandeling. Deze bevindingen onderstrepen de aanhoudende behandelachterstand en pleiten voor vroegtijdige overweging van moderne combinatietherapie bij deze patiëntengroep.","abstract_original":"HIV-associated pulmonary arterial hypertension (HIV-PAH) is rare and understudied. We pooled 12 right heart catheterization-confirmed cohorts (n = 537, 1986-2021) and found that HIV-PAH presents with severe hemodynamics and advanced functional limitation, with only 64% receiving PAH-targeted therapy at diagnosis. Survival improved progressively over three decades alongside increasing therapy use. These findings highlight persistent treatment gaps and support consideration of contemporary combination PAH therapy in people with HIV-PAH."}